- Home
- REFR vs MAIA Comparison
REFR vs MAIA Comparison
Compare REFR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- MAIA
- Stock Information
- Founded
- REFR 1965
- MAIA 2018
- Country
- REFR United States
- MAIA United States
- Employees
- REFR N/A
- MAIA N/A
- Industry
- REFR Multi-Sector Companies
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- MAIA Health Care
- Exchange
- REFR Nasdaq
- MAIA Nasdaq
- Market Cap
- REFR 49.5M
- MAIA 56.3M
- IPO Year
- REFR N/A
- MAIA 2022
- Fundamental
- Price
- REFR $1.36
- MAIA $1.54
- Analyst Decision
- REFR
- MAIA
- Analyst Count
- REFR 0
- MAIA 0
- Target Price
- REFR N/A
- MAIA N/A
- AVG Volume (30 Days)
- REFR 29.8K
- MAIA 319.0K
- Earning Date
- REFR 08-07-2025
- MAIA 08-11-2025
- Dividend Yield
- REFR N/A
- MAIA N/A
- EPS Growth
- REFR N/A
- MAIA N/A
- EPS
- REFR N/A
- MAIA N/A
- Revenue
- REFR $1,222,239.00
- MAIA N/A
- Revenue This Year
- REFR N/A
- MAIA N/A
- Revenue Next Year
- REFR N/A
- MAIA N/A
- P/E Ratio
- REFR N/A
- MAIA N/A
- Revenue Growth
- REFR N/A
- MAIA N/A
- 52 Week Low
- REFR $0.93
- MAIA $1.40
- 52 Week High
- REFR $2.35
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- REFR 42.95
- MAIA 45.97
- Support Level
- REFR $1.37
- MAIA $1.50
- Resistance Level
- REFR $1.44
- MAIA $1.75
- Average True Range (ATR)
- REFR 0.06
- MAIA 0.09
- MACD
- REFR 0.00
- MAIA 0.01
- Stochastic Oscillator
- REFR 40.00
- MAIA 25.00
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.